U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. News & Events
  3. FDA Meetings, Conferences and Workshops
  4. Recombinant Protein-Based COVID-19 Vaccines Workshop - 04/27/2023
  1. FDA Meetings, Conferences and Workshops

Workshop | Virtual

Event Title
Recombinant Protein-Based COVID-19 Vaccines Workshop
April 27, 2023

Date:
April 27, 2023
Time:
9:00 AM - 1:00 PM ET

The recording of the Recombinant Protein-Based COVID-19 Vaccines Workshop is available until Thursday, June 15, 2023. See below for the video.

The Biomedical Advanced Research and Development Authority (BARDA) and FDA are pleased to host a virtual workshop (using Zoom Platform) titled Recombinant Protein-Based COVID-19 Vaccines. The goals of the workshop are to provide: 1) a forum for product sponsors to discuss progress and technical challenges in the manufacturing when changing strain composition to currently circulating variants of SARS-CoV-2; and 2) an open forum for collaborative discussions to facilitate advancement of recombinant protein-based COVID-19 vaccines.

This workshop is a virtual event, held on April 27, 2023, from 9:00 am EDT to 1:00 pm EDT and comprised of external speakers, presentations, and panel discussions with experts in COVID-19 vaccine development from academia, government, and industry. 

Topics:

  • United States Government Partners – SARS-CoV-2 epidemiology, need for continuous investment in COVID-19 vaccines including novel and next generation vaccines
  • Product Sponsors – Challenges for timely launch of periodic updated vaccines
  • Panel Discussion – Overcoming challenges to address strain updates and pandemic readiness.

Agenda

Recording:

Topic: Workshop on Recombinant COVID-19 Vaccines
Date: April 27, 2023 9:00 AM Eastern Time (US Canada)

For Further Information Contact:

ocod@fda.hhs.gov and include the text "Recombinant COVID-19 Workshop" in the subject line.

Back to Top